EP1001 - ECE_3596 - Setmelanotide therapy in hypothalamic obesity following craniopharyngioma: a case series of three patients
Hypothalamic obesity (HO) is a severe, often treatment-refractory complication after craniopharyngioma (CP) surgery. Setmelanotide, a melanocortin-4 receptor agonist (MC4R-A), offers a targeted therapeutic approach, but real-world data are limited. We performed a retrospective review of patients with post-...